ArticleCancer research2017
Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers.
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Novel Small Molecule DZ-865B Effectively Degrades BCL6, Promotes Apoptosis and Reduces Proliferation of Diffuse Large B-Cell Lymphoma Cells.Oncology research · 2026Article
- Resveratrol as a BCL6 natural inhibitor suppresses germinal center derived Non-Hodgkin lymphoma cells growth.Journal of natural medicines · 2025Article
- Capturing cell heterogeneity in representations of cell populations for image-based profiling using contrastive learning.PLoS computational biology · 2024Article
- Capturing cell heterogeneity in representations of cell populations for image-based profiling using contrastive learning.bioRxiv : the preprint server for biology · 2024Article
- HnRNP K regulates inflammatory gene expression by mediating splicing pattern of transcriptional factors.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer.Scientific reports · 2022Article
- Knockdown of ZBTB11 impedes R-loop elimination and increases the sensitivity to cisplatin by inhibiting DDX1 transcription in bladder cancer.Cell proliferation · 2022Article
- BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.The Journal of clinical investigation · 2022Article
- Article
- Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.Nature communications · 2022Article
- Early Diagnosis and Screening for Lung Cancer.Cold Spring Harbor perspectives in medicine · 2021Review
- Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Article
- ACE2: At the crossroad of COVID-19 and lung cancer.Gene reports · 2021Review
- Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.Journal of medicinal chemistry · 2021Article
- BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.The Journal of clinical investigation · 2021Article
- Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC.Molecular & cellular proteomics : MCP · 2020Article
- A long non-coding RNA LNBC3 facilitates non-small cell lung cancer progression by stabilizing BCL6.Journal of clinical laboratory analysis · 2020Article
- Patient Stratification of Clear Cell Renal Cell Carcinoma Using the Global Transcription Factor Activity Landscape Derived From RNA-Seq Data.Frontiers in oncology · 2020Article
- Capturing single-cell heterogeneity via data fusion improves image-based profiling.Nature communications · 2019Article
- BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress.Cancer discovery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Oncogene-specific changes in cellular signaling have been widely observed in lung cancer. Here, we investigated how these alterations could affect signaling heterogeneity and suggest novel therapeutic strategies. We compared signaling changes across six human bronchial epithelial cell (HBEC) strains that were systematically transformed with various combinations of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.